You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Once finalized, lung cancer patients in England can receive the drug for two years after they've received chemotherapy and if their tumors express PD-L1.
NICE is reversing its earlier negative recommendation for the lung cancer drug after AstraZeneca agreed to provide it at a discount.
The company, which uses fruit fly "avatars" to screen drugs, will be collaborating with London IVD Co-operative and Genomics England to test their technology in GI cancer patients.
The final draft guidance recommends gilteritinib monotherapy for FLT3-mutated, relapsed or refractory AML, calling it a "cost-effective use of NHS resources."
The committee recommended the tumor-agnostic drug for use in the Cancer Drugs Fund while awaiting mature survival data from ongoing clinical trials.
The decision is based on pooled single-arm trial data demonstrating the agent's ability to prolong progression-free survival and shrink patients' tumors.
The guideline, in effect for three months, gives access to many molecularly informed indications that NICE previously found not cost-effective or that it hasn't yet reviewed.
NICE reversed an earlier decision and issued a positive recommendation after Bayer discounted the price of the drug.
Based on cost-effectiveness estimates and a lack of comparison against afatinib, NICE will recommend against using osimertinib for first-line treatment of NSCLC.
National Institute for Health and Care Excellence draft guidance suggests more data is needed before using larotrectinib to treat UK cancer cases in histology-independent setting.